Molecular mode of action of CGS 9895 at α1 β2 γ2 GABAA receptors. by Maldifassi, Maria Constanza et al.
 1 
Molecular mode of action of CGS 9895 at α1β2γ2 GABAA receptors 
 
 Maria C. Maldifassi, Roland Baur and Erwin Sigel 
 
Institute of Biochemistry and Molecular Medicine, University of Bern, CH-3012 Bern, 
Switzerland 
 
Correspondence: 
Erwin Sigel 
Bühlstrasse 28 
Institute of Biochemistry and Molecular Medicine 
University of Bern 
Phone +41 79 613 10 46 
CH-3012 Bern 
Switzerland 
E-mail: sigelatibmm.unibe.ch 
 
Keywords GABAA receptors; Chloride channels; Electrophysiology; Xenopus oocyte; 
Benzodiazepines  
Abbreviations GABA, γ-aminobutyric acid; GABAA, γ-aminobutyric type A; CGS 
9865, pyrazoloquinoline 2-p-methoxyphenylpyrazolo [4,3-c] quinolin-3(5H)-one
 2 
Abstract 
 
GABAA receptors are the main inhibitory neurotransmitter receptors in the brain and are 
targets for numerous clinically important drugs such as benzodiazepines, anxiolytics and 
anesthetics. Previously, CGS 9895 was described as a positive allosteric modulator acting 
through the α+/β− interface in the extracellular domain of GABAA receptors. The localization 
of the binding site was based on a steric hindrance approach, rather than on direct effects of 
point mutations. In the current study we further characterized modulation by this compound 
that seems to have six sites of action. We investigated GABAA receptors expressed in 
Xenopus laevis oocytes using voltage-clamp electrophysiology. We have identified the 
α1Y209 residue present at this interface as a key residue for CGS 9895 modulation. 
Additionally, the interaction between this residue and various structural analogs was 
characterized, allowing tentative positioning of CGS 9895 versus α1Y209 (rat sequence). Not 
all compounds were found to be sensitive to mutations at the α1Y209 residue. In addition, the 
interaction of CGS 9895 with flurazepam was characterized. Flurazepam is hypothesized to 
act at the same subunit interface in the extracellular domain. We also provide evidence that 
the GABAA receptor harbors additional modulatory sites for CGS 9895 at each of the subunit 
interfaces in the trans membrane domain.  
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Introduction 
 
The major inhibitory receptor in the mammalian central nervous system is the γ-aminobutyric 
acid type A (GABAA) receptor. This receptor is composed of five homologous subunits, 
arranged around a central Cl- selective channel (Macdonald et al. 1994). While 19 subunits 
have been cloned (Macdonald et al. 1994; Barnard et al. 1998; Olsen et al. 2008; Sigel and 
Steinmann 2012), the majority of GABAA receptors in the brain consist of α1, β2 and γ2 
subunits (Macdonald et al. 1994; Rabow et al. 1995; Barnard et al. 1998; Olsen et al. 2008; 
Sigel and Steinmann 2012). Subunit composition and arrangement both affect the 
pharmacological properties of GABAA receptors (Sigel et al. 1990; Sieghart 1995; Minier and 
Sigel 2004). In the following we assume that the α1β2γ2 GABAA receptor has the subunit 
arrangement γ2β2α1β2α1 and the α1β2 receptor has the subunit arrangement β2β2α1β2α1 
(Baumann et al. 2001).  
Several clinically and experimentally used drugs exert their action via GABAA receptors, 
including benzodiazepines, barbiturates, and the intravenous anesthetics propofol and 
etomidate (Sieghart 1995; Rudolph et al. 1999; Nishikawa et al. 2002; Jurd et al. 2003; 
Sieghart and Ernst 2005; Li et al. 2006; Yip et al. 2013; Middendorp et al. 2014). A high 
affinity benzodiazepine binding site on α1β2γ2 GABAA receptors is located at the α+/γ− 
subunit interface in the extracellular domain (Sigel 2002; Sigel and Lüscher 2011). This site is 
homologous to the GABA binding sites at β+/α− interfaces (Sigel and Buhr 1997; Sigel and 
Lüscher 2011). In addition to the high affinity binding site for benzodiazepines (site 1), there 
are other low affinity sites. One of these, site 2, is thought to be located at the α+/β− interface 
in the extracellular domain (Baur et al. 2008). Later it has been postulated that the 
pyrazoloquinoline CGS 9895 acts in a similar location (Ramerstorfer et al. 2011). 
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Interestingly, an ethanol antagonist site at the same subunit interface has been postulated in 
extrasynaptic δ subunit containing receptors (Wallner et al. 2014). Other sites designated as 
sites 3 (Middendorp et al. 2015), are located in the membrane and have been shown to be 
abolished by combined mutations to isoleucine of the homologous residues α1S269, β2N265, 
and γ2S280 (Walters et al. 2000).  
It has been demonstrated that CGS 9895 at nM concentrations is a null modulator at site 
1, and at µM concentrations a positive allosteric modulator acting at the α+/β− interface in 
the extracellular domain (Ramerstorfer et al. 2011).  The localization of the binding site for 
CGS 9895 was based on a steric hindrance approach using a 18 Å long reactive molecule 
rather than on direct interference of point mutations with modulation by this compound. The 
modulatory action of CGS 9895 is sensitive to the types of α and β subunit isoforms present 
in the receptor (Ramerstorfer et al. 2011). Later, additional CGS 9895 analogues acting either 
as allosteric modulators or null modulators were described (Varagic et al. 2013a; Varagic et 
al. 2013b). 
 In the present study we were interested to identify point mutations interfering with 
modulation by CGS 9895. We show that the α1Y209 residue, specifically that located at the 
α+/β− interface in α1β2γ2 GABAA receptors, is crucial for modulation of the receptor by CGS 
9895. We also describe the existence of additional modulatory sites for this compound in the 
trans membrane domain of the GABAA receptor. 
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Materials and methods 
 
Construction of mutated receptor subunits 
The point mutations α1Y209Q, α1Y209C, α1Y209F, α1S269I, β2N265I and γ2S280I were 
prepared using the QuikChangeTM mutagenesis kit (Stratagene, Agilent Technologies, Basel, 
Switzerland). The numbering of amino acid residues is based on mature rat sequences. 
 
Expression of GABAA receptors in Xenopus oocytes 
Methods used were essentially as described (Middendorp et al. 2015). Briefly, capped cRNAs 
were synthesized (Ambion, Austin, TX, USA) from the linearized plasmids with a 
cytomegalovirus promotor (pCMV vectors) containing the different subunits, respectively. A 
poly-A tail of about 400 residues was added to each transcript using yeast poly-A polymerase 
(United States Biologicals, Cleveland, OH, USA). The concentration of the cRNA was 
quantified on a formaldehyde gel using Radiant Red stain (Bio-Rad) for visualization of the 
RNA. Known concentrations of RNA ladder (Invitrogen) were loaded as standard on the same 
gel. cRNAs were precipitated in ethanol/isoamylalcohol 19:1, the dried pellet dissolved in 
water and stored at −80°C. cRNA mixtures were prepared from these stock solutions and 
stored at −80°C. 
Animal experiments were carried out in strict accordance to the Swiss ethical guidelines, and 
have been approved by the local committee of the Canton Bern Kantonstierarzt, Kantonaler 
Veterinärdienst Bern (BE85/15). Surgery of female adult Xenopus laevis was done under 
anesthesia (0.2 % tricaine solution). Oocytes were prepared, injected and defolliculated as 
described previously (Sigel 1987; Sigel and Minier 2005). Oocytes were injected with 50 nL 
of the cRNA solution containing wild-type or mutated rat α1, β2 and γ2 subunits of the 
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GABAA receptors at a concentration of 10 nM:10 nM:50 nM (Boileau et al. 2002). Injected 
oocytes were incubated in modified Barth’s solution at 18°C for at least 24 h before the 
measurements. 
 
Functional characterization of the GABAA receptors 
Currents were measured essentially as described (Middendorp et al. 2015). Briefly, we used a 
modified two-electrode voltage clamp amplifier Oocyte clamp OC-725 (Warner Instruments, 
Hamden, CT, USA) in combination with a XY-recorder (90% response time 0.1 s) or 
digitized at 100 Hz using a PowerLab 2/20 using the computer programs Chart 
(ADInstruments – Europe, Oxford, England). Electrodes were filled with 3 M KCl and had 
resistances of 0.5 – 0.8 MΩ. Tests with a model oocyte were performed to ensure linearity in 
the larger current range. The response was linear up to 15 µA. The holding membrane 
potential was −80 mV. The perfusion medium contained 90 mM NaCl, 1 mM KCl, 1 mM 
MgCl2, 1 mM CaCl2, and 5 mM Na-HEPES (pH 7.4). Concentration response curves for the 
compounds were ﬁtted with the equation I(c) = Imax/[1 + (EC50/c)n], where c is the 
concentration of the compound, EC50 the concentration eliciting half-maximal current 
amplitude, Imax is the maximal current amplitude, I the current amplitude, and n is the Hill 
coefﬁcient. Maximal current amplitudes (Imax) were obtained from the fits of the 
concentration-response curves. For all receptors studied, modulation was measured at a 
GABA concentration eliciting 0.7-1.2 % of the maximal GABA current amplitude. GABA 
was applied twice alone, and 45 s or 1 min applications in combination with the different 
compounds. The duration of washout periods was 4 min in between agonist or agonist/drug 
aplications to prevent receptor desensitization. At the beginning of the experiments, GABA 
applications were repeated when the elicited current amplitude altered by >5%. Potentiation 
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was calculated by the following equation: (IModulator + GABA/IGABA – 1) * 100%. The perfusion 
solution was applied through a glass capillary with an inner diameter of 1.35 mm, the mouth 
of which was placed about 0.4 mm from the surface of the oocyte. This allowed fast changes 
in agonist concentration around the oocyte. The rate of change was estimated 70% in less than 
0.5 s (Sigel et al. 1990). The perfusion system was cleaned between drug applications by 
washing with DMSO to avoid contamination. All media contained a final concentration of 0.5 
% DMSO (v/v) to ensure drug solubility. 
 All data are from as a minimum of three different oocytes from at least two different 
batches of oocytes. Data represent mean ± SEM. An unpaired t-test was used to compare two 
means. One-way analysis of variance (ANOVA) was used for multiple comparisons followed 
by a Tukey post hoc test.  ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001. 
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Results  
 
We were interested in determining amino acid residues important for the modulation by CGS 
9895 at GABAA receptors. The α1Y209Q mutation has been shown to abolish high affinity 
binding of Ro 15-1788 and flunitrazepam at the α+/γ− at site 1 (Buhr et al. 1997). As there 
are two α1 subunits, there are two α1Y209 residues in a α1β2γ2 receptor. We hypothesized that 
this mutation would possibly be able to interfere with modulators acting at the α+/β− 
interface. Here, we report the α1Y209 residue as a major determinant of CGS 9895 action. 
 
Effects of different point mutations of α1Y209 on potentiation by CGS 9895 
We examined the consequences of different point mutations of the α1Y209 residue on the 
potentiation by CGS 9895 of currents elicited by GABA. Wild-type α1β2γ2 receptors and three 
mutated receptors α1Y209Qβ2γ2, α1Y209Cβ2γ2 and α1Y209Fβ2γ2 were studied. These 
receptors were expressed in Xenopus oocytes, and investigated using electrophysiological 
techniques. Fig. 1a indicates the localization of this residue in the receptor, and Fig. 1b shows 
the structure of CGS 9895. For illustration, the localization of the mutations is shown in the 
crystalized homomeric β3 receptor (Miller and Aricescu 2014), where the β3 subunits were 
renamed α1, β2 and γ2. Fig. 2a shows original current traces obtained for wild-type α1β2γ2 
(top) and mutated α1Y209Qβ2γ2 (bottom) receptors. Fig. 2b summarizes the results. For all 
receptors studied, modulation was measured at a GABA concentration eliciting 0.7-1.2 % of 
the maximal GABA current amplitude. It should be noted that the mutation α1Y209Q reduces 
the EC50 for channel opening by GABA in α1β2γ2 GABAA receptors about 2-fold (Buhr et al. 
1997). Potentiation by 10 µM CGS 9895 in α1β2γ2 receptors amounted to 336 ± 6 % (mean ± 
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SEM, n = 11), and was greatly diminished in α1Y209Qβ2γ2 receptors to 38 ± 9 % (mean ± 
SEM, n = 4, p <0.0001 Tukey posthoc test) and in α1Y209Cβ2γ2 receptors 88 ± 24 % (mean ± 
SEM, n = 4, p <0.0001 Tukey posthoc test). In α1Y209Fβ2γ2 receptors potentiation was 309 ± 
15 % (mean ± SEM, n = 4, p > 0.05 Tukey posthoc test), and did not differ from the 
potentiation observed in wild-type receptors. 
To exclude interaction with the benzodiazepine binding site located at the α+/γ− 
interface, where CGS 9895 acts as a antagonist (Ramerstorfer et al. 2011), we studied the 
effect of potentiation on dual subunit α1β2 receptors. Fig. 3a illustrates original traces for α1β2 
(top) and mutant α1Y209Qβ2 (bottom) receptors. Fig. 3b shows the averaged data. In α1β2 
receptors, potentiation by 10 µM CGS 9895 amounted to 388 ± 22 % (mean ± SEM, n = 6). 
In α1Y209Qβ2 receptors potentiation was reduced to -4 ± 4 % (mean ± SEM, n = 6, p < 
0.0001 Tukey posthoc test), and in α1Y209Cβ2 receptors to 43 ± 14 % (mean ± SEM, n = 4, p 
< 0.0001 Tukey posthoc test). The α1Y209Fβ2 receptor showed a similar potentiation 
amounting to 465 ± 49 % (mean ± SEM, n = 4, p > 0.05 Tukey posthoc test) as compared to 
α1β2 receptors.  
Therefore replacement of the tyrosine in the α1209 residue by glutamine or cysteine 
leads to abolishment or a reduction of modulation by CGS 9895. A more conservative 
mutation to phenylalanine did not affect potentiation. Our results suggest that CGS 9895 acts 
through the α+/β− interface in the extracellular domain.  
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Positive allosteric modulation of GABAA receptors by CGS 9895 of α1β2γ2 and 
α1Y209Qβ2γ2 receptors 
Fig. 4 shows the concentration-response curves obtained for wild-type α1β2γ2 and 
α1Y209Qβ2γ2 receptors. The α1β2γ2 receptor was characterized by an EC50 of 7.3 ± 0.8 µM 
(mean ± SEM, n = 4), and the α1Y209Qβ2γ2 mutant receptor by an EC50 of 26 ± 3 µM (mean 
± SEM, n = 4). Thus, this mutation increased the EC50 for CGS 9895 over 3-fold as compared 
to wild-type receptors. In addition, maximal potentiation was decreased by the mutation. In 
α1β2γ2 receptor maximal potentiation amounted to 632 ± 148 % (mean ± SEM, n = 4), and in 
α1Y209Qβ2γ2 mutated receptors 252 ± 59 % (mean ± SEM, n = 4). 
 
Effect of α1Y209Q mutation on potentiation by different structural analogues of CGS 
9895 
In order to compare the different analogues, we determined the effect of the mutation at a 
concentration of the respective compound at the concentration effecting half maximal 
potentiation. We studied the effect of the above point mutation on the potentiation by the 
structural analogue LAU 177 (Fig. 5). A former report has indicated that this compound 
potentiates α1β3 receptors expressed in Xenopus oocytes with an EC50 of 1.0 ± 0.1 µM 
(Varagic et al. 2013a). Fig. 1 shows the structure of all analogues studied. LAU 177 differs 
from CGS 9895 by different substituents in positions 4 and 8. Potentiation by 1 µM LAU 177 
in α1β2γ2 receptors amounted to 478 ± 37 % (mean ± SEM, n = 4). In the mutated 
α1Y209Qβ2γ2 receptor potentiation amounted to 304 ± 30  % (mean ± SEM, n = 4, p = 0.011 
t-test). This indicates that LAU 177 is only partially affected by the mutation. 1 µM of the 
benzodiazepine antagonist Ro 15-1788 did not affect the degree of potentiation in α1β2γ2 
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receptors. Thus, we excluded that modulation was through the high affinity benzodiazepine 
binding site (not shown). 
We also examined the effect of the α1Y209Q mutation on the potentiation by 
compounds differing from CGS 9895 only in one position, LAU 176, CGS 8216 and CGS 
9896 (Fig. 1b). As above, the antagonist Ro 15-1788 excluded an action of all these 
compounds at the benzodiazepine binding site 1 (not shown). 10 µM of the compound CGS 
9896 showed a similar potentiation in mutant α1Y209Qβ2γ2 receptors with potentiation 
amounting to 177 ± 35 % (mean ± SEM, n = 4) as in wild-type α1β2γ2 receptors, with 197 ± 
14 % (mean ± SEM, n = 4, p > 0.05 t-test). In contrast, 4 µM LAU 176 showed a markedly 
decreased potentiation in α1Y209Qβ2γ2 as compared to α1β2γ2 receptors. Potentiation in 
α1β2γ2 receptors by LAU 176 in was 1607 ± 159 % (mean ± SEM, n = 4) and in the mutated 
α1Y209Qβ2γ2 receptor 249 ± 21  % (mean ± SEM, n = 4, p = 0.0001 t-test). For 10 µM CGS 
8216 potentiation was very small amounting to 56 ± 5 % (mean ± SEM, n = 4) in wild type 
receptors and to -34 ± 5  % (mean ± SEM, n = 4, p < 0.0001 t-test) in mutated α1Y209Qβ2γ2 
receptors. 
In wild-type α1β1γ2 receptors, potentiation by compound LAU 176 was dramatically 
enhanced as compared to LAU 177, whereas it was almost lost for CGS 8216. This 
observation has been made previously (Varagic et al. 2013a). Replacement in position R4 of a 
-CN substituent of -OMe is beneficial for the pair LAU 176/ LAU 177, whereas replacement 
of -OMe by a -H in this position in CGS 9895 is detrimental for potentiation. 
 
Effect of α1Y209 mutations on potentiation by flurazepam 
Since flurazepam has been hypothesized to act with low affinity at the same interface as CGS 
9895, namely the α+/β− interface at the extracellular domain (Baur et al. 2008), we wanted to 
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see if the α1Y209Q mutation affects the response to flurazepam. Thus, we studied the effect 
of the α1Y209Q mutation in the concentration response curve for flurazepam at α1β2γ2 
receptors (Fig. 6). As shown previously the concentration dependence potentiation is bell-
shaped in wild-type α1β2γ2 receptors (Baur et al. 2008). This bell shape has been interpreted 
as a positive allosteric modulation through the classical benzodiazepine site (site 1), that is 
counteracted by occupation of the site at the α+/β− interface (site 2) (Baur et al. 2008). In the 
mutated receptor, the concentration dependence of the potentiation by flurazepam was also 
bell shaped but was greatly shifted to the right. As expected this mutation interferes with the 
action of flurazepam at the classical benzodiazepine site. At concentrations above 10 µM this 
compound produced an increase of the current, passing through a maximum at 75-100 µM. 
Apparent affinities in wild-type receptors and the mutated receptors through site 1 were 0.4 ± 
0.1 µM (mean ± SEM, n = 9) and 37 ± 15 µM (mean ± SEM, n = 4) respectively.  Inhibition 
at high concentration of flurazepam has been interpreted as occupation of site 2 (Baur et al. 
2008). The point mutation increased the EC50 for site 2 from 64 ± 9 µM (mean ± SEM, n = 9) 
to 147 ± 18 µM (mean ± SEM, n = 4).  
 
Flurazepam antagonizes potentiation by CGS 9895 
Next we studied if flurazepam interferes with CGS 9895 action. For this purpose we used 100 
µM and 300 µM of flurazepam to counteract modulation by this compound. At these 
concentrations flurazepam shows reduced or no potentiation response of α1β2γ2 GABAA 
receptors (Fig. 6) (Baur et al. 2008). 10 µM of CGS 9895 potentiated the response of α1β2γ2 
receptors by 347 ± 11 % (mean ± SD, n = 3).  Subsequently, the same oocytes were exposed 
to the combination of 10 µM CGS 9895 and 100 µM of flurazepam, and a residual 
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potentiation amounting to 151 ± 10 % (mean ± SD, n = 3) was observed. In another set of 
experiments, 10 µM of CGS 9895 potentiated the response of α1β2γ2 receptor by 323 ± 10 % 
(mean ± SEM, n = 4). When the same oocytes were exposed to the combination of 10 µM 
CGS 9895 and 300 µM of flurazepam residual potentiation of 18 ± 4 % (mean ± SEM, n = 4) 
was obtained. An original current trace of the latter experiment is shown in Fig. 7. As shown 
in Fig. 6 at a concentration of 300 µM, flurazepam alone nearly fails to affect current elicited 
by GABA. In α1β2 receptors 10 µM of CGS 9895 potentiated the response by 329 ± 37 % 
(mean ± SEM, n = 4), subsequently the same oocytes were exposed to the combination of 10 
µM CGS 9895 and 300 µM of flurazepam where potentiation amounted to 73 ± 19 % (mean 
± SEM, n = 4). The above results indicate that the ability of flurazepam to inhibit modulation 
by CGS 9895 could be mediated via the same site in the extracellular α+/β− interface. 
Alternatively, both modulatory sites must communicate or the effect of their occupation 
converges at the GABA binding site or on channel gating. 
 
Possible additional sites of action of CGS 9895 
Although our observations suggest involvement of the α1Y209 residue situated at the 
extracellular α+/β− interface in the potentiation by CGS 9895, this compound could still act 
additionally at other sites in the receptor. Previously, we and others have observed that many 
hydrophobic substances act at the low affinity site for diazepam on GABAA receptors located 
at subunit interfaces in the trans membrane region (site 3). We wondered if CGS 9895 would 
also act at these sites. Triple mutant α1S269Iβ2N265Iγ2S280I receptor has previously been 
shown to lack low affinity diazepam sites (Walters et al. 2000). Each mutation is located at 
different receptor interfaces. Wild-type receptors, α1S269Iβ2γ2, α1β2N265Iγ2, α1β2γ2S280I and 
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α1S269Iβ2N265Iγ2S280I were expressed and investigated. The mutated receptors are 
abbreviated here as α1M, β2M, γ2M, and α1Mβ2Mγ2M. The potency of GABA for channel 
gating in all these mutated receptors has previously been described (Maldifassi et al. 2016). In 
order to exclude general gating effects caused by these mutations we showed that potentiation 
by low concentrations of diazepam and by THDOC were not affected (Maldifassi et al. 2016).  
First we characterized in each receptor the concentration-response relationship for the 
modulation by diazepam. As shown in Fig. 8a, in wild-type and all mutated receptor forms 
nM concentrations of diazepam potentiated GABA elicited currents. In α1β2γ2 and α1β2γ2M 
receptors the first phase of potentiation reached a plateau at approximately 0.3 µM of 
diazepam. An inhibitory phase was observed at wild-type α1β2γ2 receptors at 3-10 µM 
diazepam and an additional phase of potentiation for both receptors was evident at 
concentrations above 10-30 µM. Mutated α1Mβ2γ2, α1β2Mγ2, and α1Mβ2Mγ2M receptors 
lacked this low affinity potentiation by diazepam. The curve was bell-shaped. At high 
concentrations, approximately 10 µM and above, diazepam produced a significant inhibition 
of the response to GABA in α1Mβ2γ2, α1β2Mγ2, and α1Mβ2Mγ2M receptors.  
Subsequently, we determined the effect of individual site 3 mutations and the triple 
mutation on potentiation by 10 µM CGS 9895, 10 µM LAU 177 and 200 µM of diazepam. As 
shown in Fig. 8b, in α1Mβ2γ2 receptors potentiation by 10 µM CGS 9895 was increased to 
614 ± 123 % (mean ± SEM, n = 5, p = 0.007 Tukey posthoc test) as compared to wild-type 
receptors, where potentiation amounted to 337 ± 6 % (mean ± SEM, n = 11) respectively. 
Potentiation by CGS 9895 was reduced in the α1β2Mγ2 receptor mutant to 115 ± 15 % (mean 
± SEM, n = 4, p = 0.007 Tukey posthoc test). In α1β2γ2M receptors potentiation was increased 
and amounted to 496 ± 117 % (mean ± SEM, n = 4, p = 0.049 Tukey posthoc test). 
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Potentiation of the GABA response in α1Mβ2Mγ2M receptors was reduced to 89 ± 9 % (mean 
± SEM, n = 7, p = 0.004 Tukey posthoc test).  
The single mutations in the α1 and in the β2 subunits altered the degree of potentiation 
by 10 µM LAU 177. Modulation was also strongly impaired in the triply mutated 
α1Mβ2Mγ2M receptors. Potentiation by 10 µM LAU 177 in wild-type α1β2γ2 receptors was 
796 ± 129 % (mean ± SEM, n = 6), in the mutated α1Mβ2γ2 receptor 390 ± 65 % (mean ± 
SEM, n = 4, p = 0.0416 Tukey posthoc test), and in α1β2Mγ2 receptors amounted to 0.3 ± 4.4 
% (mean ± SEM, n = 4, p = 0.0001 Tukey posthoc test). In the triple mutated receptor 
α1Mβ2Mγ2M potentiation was 17 ± 12 % (mean ± SEM, n = 4, p = 0.0002 Tukey posthoc 
test).  
Potentiation by 200 µM diazepam was affected by all mutations. Potentiation in wild-
type receptors amounted to 348 ± 68 % (mean ± SEM, n = 4) and was reduced to 63 ± 13 % 
(mean ± SEM, n = 4, p = 0.0257 Tukey posthoc test) in the α1Mβ2Mγ2M receptor. For the 
individually mutated receptors potentiation amounted to 55 ± 17 % in α1Mβ2γ2 (mean ± SEM, 
n = 4, p = 0.036 Tukey posthoc test), -52 ± 16 % in α1β2N265Iγ2 (mean ± SEM, n = 4, p = 
0.016 Tukey posthoc test) and to 974 ± 175 % in α1β2γ2M receptor (mean ± SEM, n = 4, p = 
0.0012 Tukey posthoc test). In this case, the α1M mutation may convert CGS 9895 into a 
negative allosteric modulator. 
The above data suggest that additional modulatory sites for CGS 9895 are present at the 
α+/β−, β+/α−, γ+/β−, and α+/γ− subunit interfaces located in the trans membrane domain of 
GABAA receptors. On the other hand, the structural analog LAU 177 may harbor modulatory 
sites at the α+/γ− and β+/α− subunit interfaces. GABAA receptors harbor modulatory sites 3 
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for diazepam at α+/β−, β+/α−, γ+/β−, and α+/γ− subunit interfaces in the trans membrane 
domain. 
 
Discussion   
 
The pyrazoloquinoline CGS 9895 at nM concentrations was described as an antagonist at the 
benzodiazepine high affinity site, but at µM concentrations enhanced GABA induced currents 
in α1β3 and α1β3γ2 receptors (Ramerstorfer et al. 2011). Using a steric hindrance approach 
together with a homology model of GABAA receptors (Ernst et al. 2005), several possible 
pocket-forming amino acids at the α+/β− subunit interface were mutated to cysteine. 
Modification with MTSEA-biotin of the mutated residues α1S204C, α1V211C and β364C 
considerably reduced modulation by CGS 9895, indicating that this compound acts within 18 
Å of the mutated residues (Ramerstorfer et al. 2011). Because of the length and flexibility of 
MTSEA-biotin, specific amino acids in contact with CGS 9895 were not identified 
(Ramerstorfer et al. 2011). Our results indicate that the α1Y209 residue located at the α+/β− 
interface is important for CGS 9895 action and additionally suggest binding sites at all five 
subunit interfaces in the trans membrane region. 
As the α1β2γ2 receptor contains two α1 subunits, there are two α1Y209 residues in the 
receptor. One residue is located at the α+/γ− interface in the extracellular domain of the 
receptor (site 1), and is part of the diazepam-binding pocket (Amin et al. 1997; Buhr et al. 
1997). The other residue is located at the extracellular part of the α+/β− interface homologous 
to the residue located at site 1. Mutation to Q of the α1Y209 residue leads to loss of Ro15-
1788 and flunitrazepam binding at the high affinity diazepam site and reduces the EC50 for 
channel opening by GABA about 2-fold (Buhr et al. 1997). We studied if the mutation of this 
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residue might also interfere with the action of modulators supposedly acting at the 
extracellular α+/β− interface.  
We found that mutations in the α1Y209 residue affected the ability of CGS 9895 to 
potentiate GABA elicited currents at GABAA receptors. Replacement of tyrosine in the α1209 
residue for the non-aromatic amino acids glutamine or cysteine, led to a dramatic reduction on 
the action of CGS 9895. When the same tyrosine residue was replaced with phenylalanine, 
leading to the removal of the hydroxyl group in the benzene ring, potentiation remained 
almost unaffected. Thus, the aromatic ring in the α1Y209 residue is essential for the 
interaction of the receptor with CGS 9895. The α1Y209Q mutation led to an increase of the 
EC50 for CGS 9895, and a decrease in the maximal potentiation obtained. Similar 
observations were made in α1β2 and α1β2γ2 receptors, indicating that indeed the residue at the 
α+/β− subunit interface is important. It should be noted that in case a point mutation affects 
modulation by a compound, the corresponding residue can be involved in the formation of the 
binding pocket, or alternatively it may affect the allosteric transduction required for 
modulation. At least the ability of GABA to gate the channel is nearly unaffected by the 
α1Y209Q mutation (Buhr et al. 1997). 
 Structural analogs of CGS 9895 were investigated for their sensitivity to mutations in 
the α1Y209 residue. All compounds investigated contained a common pyrazoloquinolinone 
nucleus, with different substituents in R4 and R8 (Fig. 1b). EC50 and efficacy (10 µM) of the 
compounds in α1β3 receptors have been described elsewhere (Varagic et al. 2013a). CGS 
9895 and LAU 176, are both sensitive to the studied mutation, and have both a -OMe group at 
position R4, but they differ in the R8 position, where the first has a -H and the latter a -OMe 
group. Potentiation by CGS 9896 is not significantly affected and that by LAU 177 partially 
by the α1Y209Q mutation. CGS 9896 has a -Cl at position R4, and at R8 a hydrogen atom. 
 18 
LAU 177 has a -CN group at the position R4, and a -OMe group at R8. CGS 8216, which 
contains -H in both positions was the weakest modulator of GABA currents in α1β2γ2 
receptors. A similar result was obtained previously using α1β3 receptors (Varagic et al. 
2013a). From our observations we conclude that the methoxy group at the R4 may be 
responsible for the sensitivity of these compounds to the α1Y209Q mutation and might be 
apposed to this residue.  
Previously, a low affinity site for flurazepam has been postulated at the α+/β− subunit 
interface. We were interested if flurazepam and CGS 9895 interacted at the same site. We 
found a) that the mutation α1Y209Q not only affects modulation by CGS 9895 but also 
affects the affinity of flurazepam to site 2 and b) that 300 µM flurazepam almost completely 
prevented modulation by CGS 9895. These results could indicate that flurazepam and CGS 
9895 may share a site of action at the α+/β− extracellular interface. Different conclusions 
have been reached earlier. High concentrations of flurazepam were described to partially 
prevent the action of CGS 9895 (10 µM) in α1β3 GABAA receptors, and to inhibit GABA 
mediated currents (Ramerstorfer et al. 2011). Since this negative modulatory effect could not 
be abolished by modification with MTSEA-biotin of α1S204C, α1V211C and β364C, the 
authors concluded that flurazepam effects must be mediated through a different site 
(Ramerstorfer et al. 2011).  
The five-subunit interfaces of GABAA receptors harbor modulatory sites for high 
concentrations of diazepam (sites 3). We also investigated if CGS 9895 is affected by 
mutations in these sites. Potentiation by CGS 9895 was reduced in the triple mutant receptor 
and by the β2N265I mutation, and increased by the mutations α1S269I and γ2S280I. We 
concluded that the five-subunit interfaces of GABAA receptors bear modulatory sites for CGS 
9895. The fact the β1S290N mutation leads to loss of stimulation by CGS 9895 in α1β1 
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receptors (Ramerstorfer et al. 2011) were previously interpreted as allosteric effect. The 
structural analog LAU 177 was also sensitive to some of the site 3 mutations. Potentiation 
was reduced in the triple mutant receptor, as by the α1S269I and β2N265I mutations, however 
it was not affected by the γ2S280I mutation. Therefore only the β+/α−, α+/β−, and α+/γ− 
GABAA receptor subunit interfaces have modulatory sites for this compound.  
In summary, we show that α1Y209 at the α+/β− interface in the extracellular domain 
is a key residue for CGS 9895 action in GABAA receptors and that it may be in contact with 
the –OMe substituent of this compound. Additionally, the GABAA receptor harbors 
modulatory sites for this compound at subunit interfaces in the membrane.  
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Legends to figures 
 
 
Fig. 1 (a) Model structure of the GABAA receptor transmembrane domain. The receptor is composed 
of two α (yellow), two β (blue), and one γ (red) subunits; structures are shown in ribbon representation. 
Shown in orange are the αY209 residues located at the extracellular α+/β– and α+/γ– interfaces. The 
model structure depicts the crystalized homomeric β3 GABAA receptor (PDB structure 4COF) (Miller 
and Aricescu 2014). Some of the β3 subunits were renamed α1, β2 and γ2. (b) Chemical structures of 
the compounds studied. Right: The investigated compounds differed in their substituents at position 
R4 and R8. Left: Common pyrazoloquinolinone nucleus.  
 
Fig. 2 Potentiation of wild-type α1β2γ2 and mutated α1Y209Qβ2γ2, α1Y209Cβ2γ2, α1Y209Fβ2γ2 receptors 
by 10 µM CGS 9895. (a) Original current traces showing the potentiation of the GABA elicited 
response by 10 µM CGS 9895 in wild-type (top) and mutant α1Y209Qβ2γ2 (bottom) receptor. 
Receptors were expressed in Xenopus oocytes and electrophysiological experiments were performed. 
The holding membrane potential was −80 mV. GABA at a concentration eliciting 0.7-1.2 % of the 
maximal current amplitude (single bars) was applied twice alone and then in combination with 10 µM 
CGS 9895. The α1Y209Q mutation strongly decreased allosteric modulation. (b) Summary of the 
results obtained in wild-type, and mutant α1Y209Qβ2γ2, α1Y209Cβ2γ2, and α1Y209Fβ2γ2 receptors. 
Experiments were performed four to eleven times with different oocytes from at least three different 
batches; data are expressed as mean ± SEM.  
 
Fig. 3 Potentiation of α1β2 and mutated α1Y209Qβ2, α1Y209Cβ2, α1Y209Fβ2 receptors by 10 µM CGS 
9895. (a) Original current traces showing the potentiation of the GABA elicited response by 10 µM 
CGS 9895 in oocytes expressing α1β2 (top) and mutant α1Y209Qβ2(bottom) receptors. GABA at a 
concentration eliciting 0.7-1.2 % of the maximal current amplitude (single bars) was applied twice 
alone and then in combination with 10 µM CGS 9895. (b) Summary of the results obtained in α1β2, 
and mutant α1Y209Qβ2, α1Y209Cβ2, α1Y209Fβ2 receptors. The holding membrane potential was −80 
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mV. Experiments were performed four to six times in different oocytes from at least three different 
batches; data are expressed as mean ± SEM.  
 
Fig. 4 Concentration dependence of the positive allosteric modulation by CGS 9895 in oocytes 
expressing wild-type (closed circle) and α1Y209Qβ2γ2 (closed square) receptors. Data are shown as 
mean ± SEM, n = 4. 
 
Fig. 5 Mutations at the α1Y209 residue affect potentiation by different structural analogues of CGS 
9895. Potentiation of the GABA elicited response by 1 µM LAU 177, 4 µM LAU 176, 10 µM CGS 8216 
and 10 µM CGS 9896 in wild-type and mutant α1Y209Qβ2γ2 receptors. Experiments were performed 
four to six times using different oocytes; data are expressed as mean ± SEM.  
 
Fig. 6 Concentration-response curves obtained of flurazepam in wild-type receptors (closed circle), 
and mutant α1Y209Qβ2γ2 receptors (closed square). Experiments were carried out 4-9 times, with 
three different batches of oocytes. Results are expressed as mean ± SEM.  
 
Fig. 7 Original current traces showing inhibition of CGS 9895 induced GABAA receptor potentiation by 
flurazepam (FZM). Wild-type receptors  were expressed in Xenopus oocytes. GABA was applied two 
times, followed by co-application of the same concentration of GABA with 10 µM CGS 9895, and 
finally combined application of GABA with 10 µM CGS 9895 and 300 µM flurazepam. The holding 
membrane potential was −80 mV. Experiments were carried out 4 times with three different batches of 
oocytes, with a similar outcome. 
 
Fig. 8 (a) Concentration dependence of the positive allosteric modulation by diazepam in oocytes 
expressing different receptors: α1β2γ2 (closed circle), α1Mβ2γ2 (inverted triangle), α1β2Mγ2 (square), 
α1β2γ2M (triangle), and α1Mβ2Mγ2M (gray circle) receptors. Data is represented as mean ± SEM, n = 4-
5. (b) Summary of the results obtained by 10 µM CGS 9895, 10 µM LAU 177, and 200 µM diazepam 
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in wild-type, single mutant α1Mβ2γ2, α1β2Mγ2, α1β2γ2M and triple mutant α1Mβ2Mγ2M receptors. The 
bars indicate mean ± SEM, n = 4-5. 
 
 
 
